Drug Evaluation Committee Conveying Clinical Trial Information in an Easy-to-understand Way To Pharmaceutical Companies that Prepare Documents for Non-specialists
June 2024
In recent years, as the disclosure of information regarding clinical trials has increased and patients and members of the public have gained greater direct access to this information, issues related to the content of the disclosed information—such as the text being too difficult or incomprehensible—have also come to light.As one response to these challenges, we have compiled key considerations for conveying clinical trial information in an easy-to-understand manner, targeting pharmaceutical company staff responsible for creating documents intended for patients and members of the public who are not medical experts. We hope this document will contribute to better health communication between patients, members of the public, and pharmaceutical companies in the future.
Please note that this document is reprinted from the “Guide to Communicating Medical Research in an Easy-to-Understand Manner,” produced by the “Project for Communicating Medical Information in an Easy-to-Understand Manner.” We extend our deepest gratitude to the members of the “Project for Communicating Medical Information in an Easy-to-Understand Manner” for granting permission to reprint this material.
Japan Pharmaceutical Manufacturers Association, Drug Evaluation Committee,
Data Science Subcommittee, FY2023 Task Force 2-3